___

• 1. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012;21:57-65.
• 2. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83:373-84.
• 3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-9.
• 4. Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 2009;27:2394-401.
• 5. Centers for Disease Control and Prevention (CDC) 2011. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010.
• 6. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
• 7. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59:1102-5.
• 8. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005;192:377-86.
• 9. Vila-Corcoles A, Ochoa-Gondar O. Antipneumococcal Vaccination in COPD Patients, Chronic Obstructive Pulmonary Disease-Current Concepts and Practice. Accessed date: 27 Mart 2013. Available from: http://cdn. intechopen.com/pdfs/30179/InTechAntipneumococcal_ vaccination_in_copd_patients.pdf
• 10. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-33.
• 11. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, et al. Implications of COPD in patients admitted to the intensive care unit by communityacquired pneumonia. Eur Respir J 2006;27:1210-6.
• 12. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-51.
• 13. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417-24.
• 14. Özlü T, Bülbül Y, Özsu S. Ulusal verilerle toplum kökenli pnömoniler. Tüberk Toraks 2007;55:191-212.
• 15. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epi- d demiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:189-209.
• 16. T.C. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü. Birinci Basamak Sağlık Hizmetlerinde Çalışan Hekimler için Yaşlı Sağlığı Tanı ve Tedavi Rehberi 2010. Erişim tarihi: 2 Temmuz 2013. Available from: http://sbu. saglik.gov.tr/Ekutuphane/kitaplar/t3.pdf
• 17. Türk İç Hastalıkları Uzmanlık Derneği. Erişkin Aşılama Önerileri 2009. Erişim tarihi: 2 Temmuz 2013. Available from: http://www.tihud.org.tr/main/renderFile?id=184
• 18. Özlü T, Bülbül Y, Alataş F, Arseven O, Coşkun AŞ, Çilli A, et al. Türk Toraks Derneği Erişkinlerde Toplumda Gelişen Pnömoni Tanı ve Tedavi Uzlaşı Raporu. Türk Toraks Dergisi 2009;10(Suppl 9):1-16.
• 19. Centers for Disease Control and Prevention (CDC). Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:66-72.
• 20. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
• 21. Global Initiative for Chronic Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Diseases (Revised 2011). Accessed date: 2 Temmuz 2013. Available from: http:// www.goldcopd.org/uploads/users/files/GOLD_ Report_2011_Feb21.pdf
• 22. Centers for Disease Control and Prevention (CDC). Recommended Adult Immunization Schedule-United States-2013. Accessed date: 2 Temmuz 2013. Available from: http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule.pdf
• 23. Long SS. Principles and Practice of Pediatric Infectious Diseases Revised Reprint. 3rd ed. London: Churchill d Livingstone, An Imprint of Elsevier, 2009.
• 24. European Vaccine Initiative, Stages of vaccine development. Accessed date: 2 Temmuz 2013. Available from: http://www.euvaccine.eu/vaccines-diseases/vaccines/ stages-development
• 25. Prevenar13® Kısa Ürün Bilgisi. Accessed date: 2 Temmuz 2013. Available from: http://www.iegm.gov.tr/Folders/ KubKT/Biyolojik%20%C3%9Cr%C3%BCnler%20 %C5%9Eube%20M%C3%BCd%C3%BCrl%C3%BC%C 4%9F%C3%BC/Prevenar%2013-KT-22.10.2010_7ccf79f. pdf
• 26. Blanchard-Rohner G, Pollard AJ. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. Expert Rev Vaccines 2011;10:673-84.
• 27. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9:185-94.
• 28. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs 2012;72:1243-55.
• 29. http://www.pfizer.com/news/press-release/press-releasedetail/pfizer_presents_detailed_results_from_landmark_ community_acquired_pneumonia_immunization_trial_in_ adults_capita_evaluating_efficacy_of_prevenar_13
• 30. Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, et al. Community Acquired Pneumonia Immunisation Trial in Adults (CAPiTA) Pneumonia 3, 95 (Abstract).